On March 16, 2026,The British Medical Journal(BMJ) online published the long-term survival results of the Phase III PHILA trial. The paper was led by Academician Xu Binghe from the Cancer Hospital Chinese Academy of Medical Sciences as corresponding author, with Professor Ma Fei from the same institution and Professor Yan Min from Henan Cancer Hospital as co-first authors. In 2023, the interim progression-free survival (PFS) results of this study were already published in BMJ, and this update analysis now demonstrates a clear overall survival (OS) benefit, with a 26% reduction in mortality risk. These findings showcase "Chinese wisdom" in breast cancer treatment to the global oncology community. HER2-positive breast cancer is characterized by rapid progression and poor prognosis. Based on the CLEOPATRA trial, the combination of pertuzumab, trastuzumab, and docetaxel has become the standard first-line regimen for HER2-positive metastatic breast cancer. However, pertuzumab targe...

“Overall, the findings by Liu and colleagues may herald a new honour paradigm for blood donation, or alternatively, a new non-cash model for rewarding it. Only time will tell.” ——TheBMJ Editorials (DOI: 10.1136/bmj.s100) Prof. Zhong Liu, Prof. Simiao Chen and the team published an original study in The BMJ entitled “Impact of shifting blood donation policy from gift to honour model: staggered difference-in-differences analysis in China.” The BMJ simultaneously published a dedicated editorial and news report. The study was also disseminated through EurekAlert!, the official science-news platform of the American Association for the Advancement of Science (AAAS), and more than 3,000 major media platforms worldwide, highlighting China’s innovative contribution to global public health policy. A safe, sufficient, and accessible blood supply is fundamental to healthcare. In the early twentieth century, the commercial model helped secure blood supplies but generated serious saf...

The multifaceted dysfunction of tumor-infiltrating T cells, especiallyexhaustion and mitochondrial dysfunction, remains a major obstacle in cancer immunotherapy. Transcriptomic and epigenomic regulations of T cell dysfunction have been extensively studied, but the role of proteostasis in regulating these obstacles remains less defined. On January 14, 2026, a collaborative team led by Guideng Li(Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences) and Philip D. Greenberg(Fred Hutchinson Cancer Center) published a research article entitled “The Ubiquitin Ligase KLHL6 Drives Resistance to CD8⁺ T Cell Dysfunction” in Nature. The study revealed the mechanistic link between sustained TCR signaling and T cell exhaustion, offering novel insights into the roles of dysregulated protein signaling and impaired proteostasis in driving T cell dysfunction. By integrating computational analyses of T cell exhaustion and mitochondrial fitness atlases with in vivo CRISPR sc...